Radiosensitizing Potential of Curcumin in Different Cancer Models.
Radiosensitizing Potential of Curcumin in Different Cancer Models. Nutr Cancer. 2019 Oct 24;:1-14 Authors: Sak K Abstract Over the past decades, studies of phytochemicals as modifiers of radiotherapeutic efficacy have become increasingly popular to improve the treatment outcome of human malignancies. In the current comprehensive review article, radiosensitizing effects of curcumin, a yellow-colored polyphenolic constituent of turmeric, in various preclinical cancer models, both In Vitro and In Vivo, are presented. Attenuation of radioadaptation and augmentation of irradiation-induced cancer cell killing are achieved through multifaceted action of curcumin on suppression of prosurvival and antiapoptotic factors. Most importantly, curcumin can block radiation-triggered NF-κB signaling pathway and downregulate downstream effector proteins, thereby conferring potentiation of radioresponses. Based on the elucidated molecular mechanisms but also due to its safety profile and low cost, curcumin might be considered a promising adjuvant agent to enhance radiotherapeutic efficacy in the treatment of various cancer types formed in different human organ systems. Further efforts to translate the current preclinical knowledge to the real application of curcumin in combinatorial radiotherapeutic strategies in clinical settings are necessary. Abbreviations AKT protein kinase B ARMS alveolar rhabdomyosarcoma ATM ataxia telangiectasia mutated Bax Bcl-2-ass...
Publication date: Available online 19 September 2020Source: International Journal of Surgery Case ReportsAuthor(s): Gabriel Fridolin Hess, Katharina Glatz, Sacha I. Rothschild, Otto Kollmar, Savas Deniz Soysal, Daniel T. Boll, Raoul André Droeser, Robert Mechera
Publication date: Available online 19 September 2020Source: International Journal of Surgery Case ReportsAuthor(s): Anthony R. Perez, Mary Ellen Chiong Perez, Crisostomo E. Arcilla
Publication date: Available online 19 September 2020Source: European Journal of Surgical OncologyAuthor(s): Robert A. Nagourney, Steven Evans, Peter H. Tran, Adam J. Nagourney, Paul H. Sugarbaker
Publication date: Available online 19 September 2020Source: European Journal of Surgical OncologyAuthor(s): Loek A.W. de Jong, Nielka P. van Erp, Philip R. de Reuver
Publication date: Available online 19 September 2020Source: European Journal of Surgical OncologyAuthor(s): W.J. Koemans, J.W. van Sandick, A.D.R. Huitema
Authors: Teng M, Zhou S, Cai C, Lupien M, He HH Abstract Prostate cancer is the most commonly diagnosed non-cutaneous cancers in North American men. While androgen deprivation has remained as the cornerstone of prostate cancer treatment, resistance ensues leading to lethal disease. Forkhead box A1 (FOXA1) encodes a pioneer factor that induces open chromatin conformation to allow the binding of other transcription factors. Through direct interactions with the Androgen Receptor (AR), FOXA1 helps to shape AR signaling that drives the growth and survival of normal prostate and prostate cancer cells. FOXA1 also possesse...
Publication date: Available online 19 September 2020Source: The Journal of Molecular DiagnosticsAuthor(s): Iris van ’t Erve, Marjolein J.E. Greuter, Karen Bolhuis, Daan C.L. Vessies, Alessandro Leal, Geraldine R. Vink, Daan van den Broek, Victor E. Velculescu, Cornelis J.A. Punt, Gerrit A. Meijer, Veerle M.H. Coupé, Remond J.A. Fijneman
Publication date: Available online 19 September 2020Source: Pathology - Research and PracticeAuthor(s): Nazila Fathi Maroufi, Nima Ashouri, Zohreh Mortezania, Zahra Ashoori, Vahid Vahedian, Mohammad Taher Amirzadeh-Iranaq, Amir Fattahi, Hamid Kazemzadeh, Mariano Bizzarri, Maryam Akbarzadeh, Hamid Reza Nejabati, Yousef Faridvand, Mohammad-Reza Rashidi, Mohammad Nouri
Publication date: September 2020Source: Human Pathology: Case Reports, Volume 21Author(s): Yuri Noda, Yuko Nakanishi, Ayaka Izui, Hiroyo Takahashi, Chiya Oshiro, Hideo Inaji, Masaru Yamasaki
Conclusion: A nisin-producing probiotic, can be used to treat 'disease-altered' biofilms and promote healthier oral biofilms, which may be useful for improving patient oral health. PMID: 32944159 [PubMed]
More News: Ataxia | Bone Cancers | Brain | Cancer | Cancer & Oncology | Carcinoma | Epithelial Cancer | Ewing's Sarcoma | Head and Neck Cancer | Hepatocellular Carcinoma | HNSCC | Kidney Cancer | Leukemia | Liver Cancer | Lung Cancer | Lymphoma | Multidrug Resistance | Nanotechnology | Nasopharyngeal Cancer | Neuroblastoma | Neurology | Non-Small Cell Lung Cancer | Nutrition | Oral Cancer | Renal Cell Carcinoma | Rhabdomyosarcoma | Sarcomas | Skin Cancer | Squamous Cell Carcinoma | Study | Turmeric